Gen Digital (GEN)

Nasdaq Market Open

Gen Digital Inc. is a consumer cyber safety company that provides security, privacy and identity-protection products to individuals and families. The company owns a portfolio of well-known brands, including Norton, Avast, LifeLock, Avira, AVG, ReputationDefender and CCleaner, giving it one of the broadest consumer-focused footprints in the cybersecurity market.

Gen’s products are designed to protect people across computers, smartphones and online accounts. Its offerings include antivirus and malware protection, device security, virtual private network services, password and privacy tools, identity theft monitoring, dark web monitoring and recovery support. The LifeLock brand is particularly associated with identity protection in the United States, while Norton and Avast have long-standing recognition in consumer antivirus and digital security.

The company serves a market shaped by rising cybercrime, data breaches, phishing, online scams and growing consumer concern about privacy. Unlike enterprise cybersecurity providers that sell primarily to large organisations, Gen concentrates on households and individual users, typically through subscription-based plans. This model gives the company recurring revenue characteristics while requiring continued investment in threat detection, product integration and customer retention.

Gen Digital was formed from the combination of established consumer security businesses and uses its scale to offer multi-brand, multi-product protection across global markets. For investors, the company represents a pure-play exposure to consumer cybersecurity and identity protection, with performance influenced by subscriber growth, renewal rates, pricing, brand strength and its ability to keep pace with evolving digital threats.

26.98 USD
+0.48 (+1.83%)

Last updated

Market Cap
15.96B
P/E
16.41
P/FCF
10.48
P/S
3.19
Enterprise Value
23.75B
Sector
Industrials
Industry
Prepackaged Software
Address
60 E RIO SALADO PARKWAY, TEMPE, AZ, 85281
GlobeNewswire Inc.

Former LifeLock Leader Steve Blackford Joins PrivacyHawk as Chief Marketing Officer

25 Nov 2025, 07:34 AM
GlobeNewswire Inc.

GAINEY McKENNA & EGLESTON Announces Proposed Class Action Settlement on Behalf of Purchasers of Symantec Corporation n/k/a Gen Digital Inc. Common Stock in the Symantec Corporation Employee Stock Purchase Plan - GEN

04 Sept 2024, 21:00 PM
GlobeNewswire Inc.

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

28 Jun 2024, 14:00 PM
GlobeNewswire Inc.

Completion of Share Buy-back Program

28 Jun 2024, 05:00 AM
GlobeNewswire Inc.

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

27 Jun 2024, 07:03 AM
GlobeNewswire Inc.

Transactions in Connection with Share Buy-back Program

24 Jun 2024, 21:55 PM
GlobeNewswire Inc.

Transactions in Connection with Share Buy-back Program

17 Jun 2024, 21:33 PM
GlobeNewswire Inc.

Grant of Restricted Stock Units and Warrants to Employees in Genmab

13 Jun 2024, 03:45 AM
Zacks Investment Research

Gen Digital (GEN) is a Top-Ranked Growth Stock: Should You Buy?

12 Jun 2024, 21:45 PM
Zacks Investment Research

Are Business Services Stocks Lagging Inter & Co. Inc. (INTR) This Year?

12 Jun 2024, 21:40 PM
GlobeNewswire Inc.

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

12 Jun 2024, 02:50 AM
Zacks Investment Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

11 Jun 2024, 21:40 PM
GlobeNewswire Inc.

Transactions in Connection with Share Buy-back Program

10 Jun 2024, 22:18 PM
Zacks Investment Research

Time to Buy the Surge in CrowdStrike's (CRWD) Stock After Earnings?

06 Jun 2024, 06:27 AM
GlobeNewswire Inc.

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

06 Jun 2024, 00:51 AM
Zacks Investment Research

Here's Why Gen Digital (GEN) is a Promising Portfolio Pick Now

03 Jun 2024, 21:54 PM
GlobeNewswire Inc.

Transactions in Connection with Share Buy-back Program

03 Jun 2024, 21:09 PM
GlobeNewswire Inc.

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

03 Jun 2024, 21:00 PM
GlobeNewswire Inc.

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

03 Jun 2024, 05:30 AM
GlobeNewswire Inc.

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

01 Jun 2024, 22:00 PM
Market Cap
15.96B
Enterprise Value
23.75B
P/E
16.41
P/B
6.11
P/S
3.19
EV / EBITDA
8.97
EV / Sales
4.75
EPS
1.62
Dividend Yield
1.95%
P/FCF
10.48
P/CF
10.33
Free Cash Flow
1.52B
ROE
37.27%
ROA
6.24%
Debt / Equity
3.14
Current Ratio
0.4
Quick Ratio
0.4
Cash
0.15
Avg Volume
8.35M
Fundamentals Snapshot Price
26.5

Income Statement

Line Item 2026 Q4 2026 Q3 2026 Q2 2026 Q1 2025 Q4
Revenue 1.28B 1.24B 1.22B 1.26B 1.01B
Gross profit 1.01B 972M 954M 990M 811M
Operating income 803M 433M 438M 446M 417M
EBITDA 932M 570M 567M 579M 527M
Net income 512M 192M 134M 135M 142M
Basic EPS 0.84 0.31 0.22 0.22 0.23
Diluted EPS 0.83 0.31 0.21 0.22 0.23

Balance Sheet

Line Item 2026 Q4 2026 Q3 2026 Q2 2026 Q1 2025 Q4
Total assets 15.59B 15.83B 16.05B 16.36B 15.5B
Total liabilities 12.98B 13.5B 13.59B 14B 13.23B
Total equity 2.61B 2.33B 2.46B 2.37B 2.27B
Cash & equivalents 411M 619M 701M 828M 1.01B
Current assets 1.08B 1.25B 1.29B 1.43B 1.44B
Current liabilities 2.71B 2.69B 2.55B 2.86B 2.85B

Cash Flow

Line Item 2026 Q4 2026 Q3 2026 Q2 2026 Q1 2025 Q4
Operating cash flow 479M 541M 116M 409M 473M
Investing cash flow -189M 58M -7M -873M -83M
Financing cash flow -499M -682M -242M 290M -296M
Change in cash -208M -82M -127M -178M 123M
Kind Filing Date Link
edgar index 10-K — Gen Digital Inc. View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
edgar index 4 — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — KO BRYAN SEUK View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
edgar index 8-K — Gen Digital Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — KO BRYAN SEUK View Filing
form 4 Form 4 — KO BRYAN SEUK View Filing
form 4 Form 4 — KO BRYAN SEUK View Filing
form 4 Form 4 — KO BRYAN SEUK View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
edgar index SCHEDULE 13G — Gen Digital Inc. View Filing
edgar index SCHEDULE 13G — Gen Digital Inc. View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — KO BRYAN SEUK View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
edgar index 8-K — Gen Digital Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
edgar index 4 — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
form 4 Form 4 — DERSE NATALIE MARIE View Filing
form 4 Form 4 — KO BRYAN SEUK View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
form 4 Form 4 — Pilette Vincent View Filing
edgar index 10-Q — Gen Digital Inc. View Filing
edgar index 8-K — Gen Digital Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — Gen Digital Inc. View Filing
edgar index 144 — Gen Digital Inc. View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
edgar index 4 — Gen Digital Inc. View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
edgar index 4 — Gen Digital Inc. View Filing
form 4 Form 4 — Chrystal John C View Filing
form 4 Form 4 — Chrystal John C View Filing
edgar index 10-Q — Gen Digital Inc. View Filing
edgar index 8-K — Gen Digital Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Gen Digital Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — Gen Digital Inc. View Filing
edgar index 4 — Gen Digital Inc. View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
form 4 Form 4 — Vlcek Ondrej View Filing
edgar index SCHEDULE 13G/A — Gen Digital Inc. View Filing
edgar index 8-K — Gen Digital Inc. View Filing